Fig. 3From: The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney diseaseDiscounted cost breakdown for modelled CKD patients receiving optimal serum potassium management to enable ongoing RAASi therapy (treatment arm), compared against patients not receiving RAASi to maintain normokalaemia (control arm). CKD chronic kidney disease, CV cardiovascular event, RAASi renin-angiotensin-aldosterone system inhibitor, RRT renal replacement therapyBack to article page